Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
The comparative antitumour activity of cisplatin, JM8 and JM9 was tested using a panel of different heterotransplanted human testicular tumour cell lines. All drugs were applied at equitoxic doses in a 5 day schedule. In the two cisplatin sensitive cell lines 2102 EP and H 12.1 both analogues were inferior to cisplatin. No significant therapeutic effect was achieved with any of the three drugs in the cisplatin resistant line H 23.1. Thus JM8 and JM9 seem to be less active in cisplatin sensitive tumours and seem to be of no advantage in the case of cisplatin resistance.